Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease

Advances in Therapy

Volumn 32, Issue 11, 2015, Pages 1029-1064

  Roussel, Ronan ^a,b,c   Lorraine, Joanne ^d   Rodriguez, Angel ^e   Salaun Martin, Carole ^f,g  

^a BICHAT HOSPITAL   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d ELI LILLY AND COMPANY   (United States)

^e Lilly Spain ^*  (Spain)

^f Eli Lilly   (France)

^g Hopital Max Fourestier   (France)

Author keywords

Antidiabetic agents; Chronic kidney disease; Diabetic nephropathy; Guidelines; Hyperglycemia; Hypoglycemia; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE RECEPTOR AGONIST; INSULIN DERIVATIVE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2;

CHRONIC KIDNEY DISEASE; DATA ANALYSIS; DIABETIC PATIENT; DISEASE SEVERITY; DRUG SAFETY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AGONISTS; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; EUROPE; GLUCOSE BLOOD LEVEL; RENAL INSUFFICIENCY, CHRONIC;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; EUROPE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RECEPTORS, GLUCAGON; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84948577375     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0261-x     Document Type: Review

References (180)

1. International Diabetes Federation. IDF diabetes atlas, 6th ed; 2014. http://www.idf.org/sites/default/files/Atlas-poster-2014_EN.pdf. Accessed 20 April 15.
2. Detournay B, Simon D, Guillausseau PJ, Joly D, Verges B, Attali C, et al. Chronic kidney disease in type 2 diabetes patients in France: prevalence, influence of glycaemic control and implications for the pharmacological management of diabetes. Diabetes Metab. 2012;38:102–12.
3. World Health Organization. Diabetes. Fact sheet 312; 2013. http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed 28 Oct 14.
4. Coll-de-Tuero G, Mata-Cases M, Rodriguez-Poncelas A, Pepió JM, Roura P, Benito B, et al. Chronic kidney disease in the type 2 diabetic patients: prevalence and associated variables in a random sample of 2642 patients of a Mediterranean area. BMC Nephrol. 2012;13:87.
5. Lou Arnal LM, Campos Gutiérrez B, Cuberes Izquierdo M, Gracia García O, Turón Alcaine JM, Bielsa García S, et al. Prevalencia de enfermedad renal crónica en pacientes con diabetes mellitus tipo 2 atendidos en atención primaria. Nefrologia. 2010;30:552–6.
6. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant. 2006;21:88–92.
7. New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, et al. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med. 2007;24:364–9.
8. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608–17.
9. Watanabe Y, Fujii H, Aoki K, Kanazawa Y, Miyakawa T. A cross-sectional survey of chronic kidney disease and diabetic kidney disease in Japanese type 2 diabetic patients at four urban diabetes clinics. Intern Med. 2009;48:411–4.
10. Narenpitak S, Narenpitak A. Prevalence of chronic kidney disease in type 2 diabetes in primary health care unit of Udon Thani Province, Thailand. J Med Assoc Thai. 2008;91:1505–13.
11. Kainz A, Hronsky M, Stel VS, Jager KJ, Geroldinger A, Dunkler D, et al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. Nephrol Dial Transplant. 2015;30(Suppl 4):iv113–8.
12. Réseau, Epidémiologie, Information, Néphrologie (REIN). Rapport annuel 2008. http://www.soc-nephrologie.org/PDF/enephro/registres/rapport_2008/rapport_2008.pdf. Accessed 28 Oct 14.
13. United States Renal Data System. Annual data report, 2013. Atlas of CKD and ESRD. Volume 2: Atlas ESRD. Incidence, prevalence, patient characteristics and modalities; 2013. http://www.usrds.org/2013/pdf/v2_ch1_13.pdf. Accessed 28 Oct 14.
14. Canadian Institute for Health Information, Canadian Organ Replacement Register Annual Report: Treatment of end stage organ failure in Canada, 2001 to 2010 (Ottawa, Ont.: CIHI, 2011). https://secure.cihi.ca/free_products/2011_CORR_Annua_Report_EN.pdf. Accessed 31 Aug 2015.
15. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–96.
16. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21(Suppl 1):1–87.
17. National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012;60:850–86.
18. Canadian Diabetes Association. Appendix 6. Therapeutic considerations for renal impairment. Can J Diabetes. 2013;37:S197–212.
19. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
20. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19(Suppl 2):327–36.
21. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(Suppl. 1):S1–266.
22. Poggio ED, Wang X, Greene T, Van Lente F, Hall PM. Performance of the modification of diet in renal disease and Cockcroft–Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol. 2005;16:459–66.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
24. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.
25. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–30.
26. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.
27. Perkovic V, Heerspink HL, Chalmers J, Woodward M, Jun M, Li Q, et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int. 2013;83:517–23.
28. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–17.
29. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
30. Cavanaugh KL. Diabetes management issues for patients with chronic kidney disease. Clin Diabetes. 2007;25:90–7.
31. Berns JS. Management of hyperglycemia in diabetics with end-stage renal disease. UpToDate. 2012. http://www.uptodate.com/contents/management-of-hyperglycemia-in-diabetics-with-end-stage-renal-disease. Accessed 5 June 2013.
32. Shima K, Chujo K, Yamada M, Komatsu M, Noma Y, Mizuguchi T. Lower value of glycated haemoglobin relative to glycemic control in diabetic patients with end-stage renal disease not on hemodialysis. Ann Clin Biochem. 2012;49:68–74.
33. Freedman BI, Shihabi ZK, Andries L, Cardona CY, Peacock TP, Byers JR, et al. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol. 2010;31(5):375–9.
34. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG. Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med. 1996;13:514–9.
35. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis. 2002;39:297–307.
36. Ng JM, Cooke M, Bhandari S, Atkin SL, Kilpatrick ES. The effect of iron and erythropoietin treatment on the HbA1C of patients with diabetes and chronic kidney disease. Diabetes Care. 2010;33:2310–3.
37. Chen HS, Wu TE, Lin HD, Jap TS, Hsiao LC, Lee SH, et al. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4. Am J Kidney Dis. 2010;55:867–74.
38. Hayashino Y, Fukuhara S, Akiba T, Akizawa T, Asano Y, Saito A, et al. Diabetes, glycaemic control and mortality risk in patients on haemodialysis: the Japan Dialysis Outcomes and Practice Pattern Study. Diabetologia. 2007;50:1170–7.
39. Riveline J-P, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, et al. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. Nephrol Dial Transplant. 2009;24:2866–71.
40. American Diabetes Association. Standards of medical care in diabetes—2011. Diabetes Care. 2011;34(Suppl 1):S11–61.
41. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, McFarlane P, Gilbert RE, MacCallum L, Senior P. Chronic kidney disease in diabetes. Can J Diabetes. 2013;37 Suppl 1:S129–36.
42. Merck Serono Limited. Glucophage (metformin hydrochloride 500 and 850 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/EMC/medicine/1043/SPC. Accessed 4 Nov 2015.
43. Sanofi-aventis Canada Inc. Glucophage (metformin hydrochloride 500 and 850 mg tablets) product monograph (Canada); 2014. http://www.sanofi.ca/products/en/glucophage.pdf. Accessed 4 Nov 2015.
44. Bristol-Myers Squibb Company. Glucophage (metformin hydrochloride 500, 850 and 1000 mg tablets) and Glucophage XR (metformin hydrochloride extended-release 500 and 750 mg tablets) label (US); 2009. http://packageinserts.bms.com/pi/pi_glucophage.pdf. Accessed 4 Nov 2015.
45. Pfizer Limited. Minodiab (glipizide 5 mg tablets) summary of product characteristics (EU); 2014. http://www.medicines.org.uk/emc/medicine/9851. Accessed 4 Nov 2015.
46. Actavis UK Ltd. Gliclazide (80 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/24126. Accessed 4 Nov 2015.
47. Servier Canada Inc. Gliclazide MR (30 and 60 mg modified release tablets) product monograph (Canada); 2012. http://www.servier.ca/sites/default/files/webform/Products/EN-DIAMICRONMR-PI.pdf. Accessed 4 Nov 2015.
48. Teva UK Limited. Glibenclamide (5 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/30410. Accessed 4 Nov 2015.
49. Sanofi-aventis Canada Inc. Diaßeta (glyburide 2.5 and 5 mg tablets) product monograph (Canada); 2013. http://products.sanofi.ca/en/diabeta.pdf. Accessed 4 Nov 2015.
50. Sanofi-aventis U.S. LLC. Diaßeta (glyburide 1.25, 2.5 and 5 mg tablets) label (US); 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017532s030lbl.pdf. Accessed 4 Nov 2015.
51. Zentiva. Amaryl (glimepiride 1 mg tablets) summary of product characteristics (EU); 2013. http://www.medicines.org.uk/emc/medicine/27034. Accessed 4 Nov 2015.
52. Sanofi-aventis Canada Inc. Amaryl (glimepiride 1, 2 and 4 mg tablets) product monograph (Canada); 2013. http://products.sanofi.ca/en/amaryl.pdf. Accessed 4 Nov 2015.
53. Sanofi-aventis. Glimepiride (1, 2 and 4 mg tablets) label (US); 2013. http://products.sanofi.us/amaryl/amaryl.pdf. Accessed 4 Nov 2015.
54. Novo Nordisk Canada Inc. GlucoNorm (repaglinide 0.5, 1 and 2 mg tablets) product monograph (Canada); 2015. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/wwwnovonordisk-ca/OurProducts/PDF/gluconorm-product-monograph-english.pdf. Accessed 4 Nov 2015.
55. Novo Nordisk Limited. Prandin (repaglinide 0.5, 1 and 2 mg tablets) summary of product characteristics (EU); 2012. http://www.medicines.org.uk/emc/medicine/18980. Accessed 4 Nov 2015.
56. Novo Nordisk Inc. Prandin (repaglinide 0.5, 1 and 2 mg tablets) label (US); 2008. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020741s035lbl.pdf. Accessed 4 Nov 2015.
57. Novartis Pharmaceuticals UK Ltd. Starlix (nateglinide 60 mg tablets) summaries of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/4622. Accessed 4 Nov 2015.
58. Novartis Pharmaceuticals Corporation. Starlix (nateglinide 60 and 120 mg tablets) label (US); 2013. https://www.pharma.us.novartis.com/product/pi/pdf/Starlix.pdf. Accessed 4 Nov 2015.
59. Novartis Pharmaceuticals Canada Inc. Starlix (nateglinide 60 and 120 mg tablets) product monograph (Canada); 2011. http://www.ask.novartispharma.ca/resources.htm?letter=S. Accessed 4 Nov 2015.
60. Bayer PLC. Glucobay (acarbose 50 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/19972. Accessed 4 Nov 2015.
61. Bayer Inc. Glucobay (acarbose 50 and 100 mg tablets) product monograph (Canada); 2014. http://www.bayer.ca/omr/online/glucobay-pmen-21nov2014-137275_l3-1.pdf. Accessed 4 Nov 2015.
62. Bayer HealthCare Pharmaceuticals Inc. Precose (acarbose 25, 50 and 100 mg tablets) label (US); 2011. http://www.univgraph.com/bayer/inserts/precose.pdf. Accessed 4 Nov 2015.
63. Bayer Pharma AG. Diastabol (miglitol 50 and 100 mg tablets) summary of product characteristics (EU); 2013. http://db.cbgmeb.nl/mri/spc/nlh-0116-001-002.pdf. Accessed 4 Nov 2015.
64. Bayer HealthCare Pharmaceuticals Inc. Glyset (miglitol 25, 50 and 100 mg tablets) label (US); 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf. Accessed 4 Nov 2015.
65. GlaxoSmithKline. Avandia (rosiglitazone 2, 4 and 8 mg tablets) label (US); 2014. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Avandia/pdf/AVANDIA-PI-MG.PDF. Accessed 4 Nov 2015.
66. GlaxoSmithKline Inc. Avandia (rosiglitazone 2, 4 and 8 mg tablets) product monograph (Canada); 2012. http://www.gsk.ca/english/docspdf/product-monographs/Avandia.pdf. Accessed 4 Nov 2015.
67. Takeda UK Ltd. Actos (pioglitazone hydrochloride 15, 30 and 45 mg tablets) summary of product characteristics (EU); 2014. http://www.medicines.org.uk/emc/medicine/4236. Accessed 4 Nov 2015.
68. Takeda Pharmaceuticals America, Inc. Actos (pioglitazone hydrochloride 15, 30 and 45 mg tablets) label (US); 2013. http://general.takedapharm.com/content/file.aspx?filetypecode=actospi&cacheRandomizer=381ab232-181d-4af2-8357-512c42b6aeb9. Accessed 4 Nov 2015.
69. Takeda Canada, Inc. Actos (pioglitazone hydrochloride 15, 30 and 45 mg tablets) product monograph (Canada); 2012. http://www.takedacanada.com/actospm/~/media/countries/ca/files/product%20pdfs/actos%20pm%20eng%2018-may-2012.pdf. Accessed 4 Nov 2015.
70. Merck Sharp & Dohme Corp. Januvia (sitagliptin 25, 50 and 100 mg tablets) label (US); 2010. https://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf. Accessed 4 Nov 2015.
71. Merck Sharp & Dohme Limited. Januvia (sitagliptin 25, 50 and 100 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/19609. Accessed 4 Nov 2015.
72. Merck Canada Inc. Januvia (sitagliptin 25, 50 and 100 mg tablets) product monograph (Canada); 2015. http://www.merck.ca/assets/en/pdf/products/JANUVIA-PM_E.pdf. Accessed 4 Nov 2015.
73. Bristol-Myers Squibb Company. Onglyza (saxagliptin 2.5 and 5 mg tablets) label (US); 2015. http://www.azpicentral.com/onglyza/pi_onglyza.pdf#page=1. Accessed 4 Nov 2015.
74. Bristol Myers Squibb-AstraZeneca EEIG. Onglyza (saxagliptin 2.5 and 5 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/22315. Accessed 4 Nov 2015.
75. Bristol-Myers Squibb Canada. Onglyza (saxagliptin 2.5 and 5 mg tablets) product monograph (Canada); 2015. http://www.astrazeneca.ca/cs/BlobServer?blobcol=pdffile&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDTType&blobheadervalue1=inline%3B+filename%3DProduct-Monograph.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobnocache=true&blobtable=AZ_FixedURLPDF&blobwhere=1285585477756&ssbinary=true. Accessed 4 Nov 2015.
76. Novartis Pharmaceuticals UK Ltd. Galvus (vildagliptin 50 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/20734. Accessed 4 Nov 2015.
77. Takeda Pharmaceuticals America, Inc. Nesina (alogliptin 6.25, 12.5 and 25 mg tablets) label (US); 2015. http://general.takedapharm.com/content/file.aspx?applicationcode=5D2277FD-CFC0-423C-B543-811D41F4771E&filetypecode=NESINAPI&cacheRandomizer=2fe2d4d7-e399-459e-b1ce-c309c559e46c. Accessed 4 Nov 2015.
78. Takeda UK Ltd. Vipidia (alogliptin 6.25, 12.5 and 25 mg tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/28513. Accessed 4 Nov 2015.
79. Takeda Canada Inc. Nesina (alogliptin 6.25, 12.5 and 25 mg tablets) product monograph (Canada); 2014. http://www.takedacanada.com/nesinapm/~/media/countries/ca/files/product%20pdfs/nesinapm_eng_2014nov07_v2.pdf. Accessed 4 Nov 2015.
80. Boehringer Ingelheim Pharmaceuticals, Inc. Tradjenta (linagliptin 5 mg tablets) label (US); 2015. http://docs.boehringeringelheim.com/Prescribing%20Information/PIs/Tradjenta/Tradjenta.pdf. Accessed 4 Nov 2015.
81. Boehringer Ingelheim Limited. Trajenta (linagliptin 5 mg tablets) summary of product characteristics (EU); 2014. http://www.medicines.org.uk/emc/medicine/25000. Accessed 4 Nov 2015.
82. Boehringer Ingelheim (Canada) Ltd. Trajenta (linagliptin 5 mg tablets) product monograph (Canada); 2015. http://www.boehringeringelheim.ca/content/dam/internet/opu/ca_EN/documents/humanhealth/product_monograph/TrajentaPMEN.pdf. Accessed 4 Nov 2015.
83. Bristol-Myers Squibb Company. Farxiga (dapagliflozin 5 and 10 mg tablets) label (US); 2014. http://www1.astrazenecaus.com/pi/pi_farxiga.pdf. Accessed 4 Nov 2015.
84. Bristol Myers Squibb-AstraZeneca EEIG. Forxiga (dapagliflozin 5 and 10 mg tablets) summary of product characteristics (EU); 2014.http://www.medicines.org.uk/emc/medicine/27188. Accessed 4 Nov 2015.
85. AstraZeneca Canada Inc. (dapagliflozin 5 and 10 mg tablets) product monograph (Canada); 2014. https://www.cadth.ca/sites/default/files/cdr/monograph/Forxiga_monograph.pdf. Accessed 4 Nov 2015.
86. Janssen Pharmaceuticals, Inc. Invokana (canagliflozin 100 and 300 mg tablets) label (US); 2015. https://www.invokanahcp.com/prescribinginformation.pdf. Accessed 4 Nov 2015.
87. Janssen-Cilag Ltd. Invokana (canagliflozin 100 and 300 mg tablets) summaries of product characteristics (one for each dose) (EU); 2015. http://www.medicines.org.uk/emc/medicine/28400. Accessed 4 Nov 2015.
88. Janssen, Inc. Invokana (canagliflozin 100 and 300 mg tablets) product monograph (Canada); 2014. https://www.cadth.ca/media/cdr/monograph/Invokana_Product%20Monograph.pdf. Accessed 4 Nov 2015.
89. Boehringer Ingelheim Limited. Jardiance (empagliflozin tablets) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/28973. Accessed 4 Nov 2015.
90. Boehringer Ingelheim Limited. Jardiance (empagliflozin tablets) label (US); 2015. http://docs.boehringeringelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf. Accessed 4 Nov 2015.
91. Amylin Pharmaceuticals, Inc. Byetta (exenatide 250 mcg/mL solution for injection) label (US); 2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf. Accessed 4 Nov 2015.
92. Bristol Myers Squibb-AstraZeneca EEIG. Byetta (exenatide 0.25 mg/mL solution for injection) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/19257. Accessed 4 Nov 2015.
93. Bristol-Myers Squibb Canada. Byetta (exenatide 250 µg/mL solution for injection) product monograph (Canada); 2013. http://www.bmscanada.ca/static/products/en/pm_pdf/Byetta_PM_E_%202013-07-3_APP_CLN.pdf. Accessed 4 Nov 2015.
94. Bristol Myers Squibb-AstraZeneca EEIG. Bydureon (exenatide prolonged-release 2 mg suspension for injection) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/24665. Accessed 4 Nov 2015.
95. AstraZeneca Pharmaceuticals LP. Bydureon (exenatide extended release 2 mg suspension for injection) label (US); 2012. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf. Accessed 4 Nov 2015.
96. Novo Nordisk Canada Inc. Victoza (liraglutide 6 mg/ml solution for injection) product monograph (Canada); 2014. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/wwwnovonordisk-ca/OurProducts/PDF/victoza-product-monograph.pdf. Accessed 4 Nov 2015.
97. Novo Nordisk Limited. Victoza (liraglutide 6 mg/ml solution for injection) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/21986. Accessed 4 Nov 2015.
98. Novo Nordisk Inc. Victoza (liraglutide 6 mg/ml solution for injection) label (US); 2015. http://www.novo-pi.com/victoza.pdf. Accessed 4 Nov 2015.
99. Sanofi-aventis groupe. Lyxumia (lixisenatide 100 mcg/ml) summary of product characteristics (EU); 2014. http://www.medicines.org.uk/emc/medicine/27406. Accessed 4 Nov 2015.
100. GlaxoSmithKline Trading Services Limited. Eperzan (albiglutide 30 mg powder and solvent for solution for injection) summary of product characteristics (EU); 2014.http://ec.europa.eu/health/documents/communityregister/2015/20150619132336/anx_132336_en.pdf. Accessed 4 Nov 2015.
101. GlaxoSmithKline LLC. Tanzeum (albiglutide 30 mg powder and solvent for solution for injection) label (US); 2015. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tanzeum/pdf/TANZEUM-PI-MG-IFUCOMBINED.PDF. Accessed 4 Nov 2015.
102. Lilly USA, LLC. Trulicity (dulaglutide 1.5 and 3.0 mg/mL) label (US); 2015. http://pi.lilly.com/us/trulicity-uspi.pdf. Accessed 4 Nov 2015.
103. Eli Lilly and Company. Trulicity (dulaglutide 1.5 and 3.0 mg/mL)solution for injection. summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/29747. Accessed 4 Nov 2015.
104. Eli Lilly Canada Inc. Humulin R; Humulin N (human insulin; regular [R] and NPH [N] 100 units/mL solutions for injection) product monograph (Canada); 2013. http://www.lilly.ca/en/pdf/consumer-information/18_humulin-ncart-kwikpen_ci_22oct2013.pdf. Accessed 4 Nov 2015.
105. Novo Nordisk Canada Inc. NovoRapid (insulin aspart 100 U/mL solution for injection) product monograph (Canada); 2014. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/wwwnovonordisk-ca/OurProducts/PDF/novorapid-product-monograph.pdf. Accessed 4 Nov 2015.
106. Novo Nordisk Limited. NovoRapid (insulin aspart 100 U/mL solution for injection) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/25033. Accessed 4 Nov 2015.
107. Novo Nordisk Inc. NovoRapid (insulin aspart 100 U/mL solution for injection) label (US); 2015. http://www.novopi.com/novolog.pdf. Accessed 4 Nov 2015.
108. Novo Nordisk Limited. Tresiba (insulin degludec 200 units/mL solution for injection) summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/27363. Accessed 4 Nov 2015.
109. Novo Nordisk Canada Inc. Levemir (insulin detemir 100 U/mL solution for injection) product monograph (Canada); 2013. http://www.novonordisk.ca/content/dam/Canada/AFFILIATE/wwwnovonordisk-ca/OurProducts/PDF/levemir-product-monograph.pdf. Accessed 4 Nov 2015.
110. Novo Nordisk Inc. Levemir (insulin detemir 100 U/mL solution for injection) label (US); 2015. http://www.novopi.com/levemir.pdf. Accessed 4 Nov 2015.
111. Novo Nordisk Canada Inc. Levemir (insulin detemir 100 U/mL solution for injection) summary of product characteristics (EU); 2015.http://www.medicines.org.uk/emc/medicine/14584. Accessed 4 Nov 2015.
112. Sanofi-aventis Canada Inc. Lantus (insulin glargine 100 U/mL solution for injection) product monograph (Canada); 2014. http://products.sanofi.ca/en/lantus.pdf. Accessed 4 Nov 2015.
113. Sanofi-aventis U.S. LLC. Lantus (insulin glargine [rDNA origin] injection) solution for subcutaneous injection label (US); 2015. http://products.sanofi.us/lantus/lantus.html. Accessed 4 Nov 2015.
114. Sanofi-aventis groupe. Lantus (insulin glargine [rDNA origin] injection) solution for subcutaneous injection summary of product characteristics (EU); 2015. http://www.medicines.org.uk/emc/medicine/25506. Accessed 4 Nov 2015.
115. Sanofi-aventis Deutschland GmbH. Apidra (insulin glulisine 100 U/mL solution for injection) summary of product characteristics (EU); 2013. http://www.medicines.org.uk/emc/medicine/26478. Accessed 4 Nov 2015.
116. Sanofi-aventis Canada Inc. Apidra (insulin glulisine 100 U/mL solution for injection) product monograph (Canada); 2014. http://products.sanofi.ca/en/apidra.pdf. Accessed 4 Nov 2015.
117. Sanofi-aventis U.S. LLC. Apidra (insulin glulisine 100 U/mL solution for injection) label (US); 2015. http://products.sanofi.us/apidra/apidra.html. Accessed 4 Nov 2015.
118. Eli Lilly Canada Inc. Humalog (insulin lispro 100 units/mL solution for injection) product monograph (Canada); 2015. http://www.lilly.ca/en/pdf/product-monograph/14_humalogpm_30mar2015.pdf. Accessed 4 Nov 2015.
119. Lilly USA, LLC. Humalog (insulin lispro injection, USP [rDNA origin]) for injection label (US); 2015. http://pi.lilly.com/us/humalog-pen-pi.pdf. Accessed 4 Nov 2015.
120. Eli Lilly and Company. Humalog (insulin lispro 100 units/mL solution for injection) summary of product characteristics (EU); 2014. http://www.medicines.org.uk/emc/medicine/9314. Accessed 4 Nov 2015.
121. Pfizer Inc. Glucotrol (glipizide 2.5, 5 and 10 mg tablets) label (US); 2013. http://labeling.pfizer.com/showlabeling.aspx?id=579. Accessed 4 Nov 2015.
122. Iglesias P, Díez JJ. Insulin therapy in renal disease. Diabetes Obes Metab. 2008;10(10):811–23.
123. Valeant Canada LP. Glumetza (metformin hydrochloride extended-release 500 and 1000 mg tablets) product monograph (Canada); 2007. http://www.valeant.com/Portals/25/Pdf/products/PI/glumetza.pdf. Accessed 4 Nov 2015.
124. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol. 1995;35:1094–102.
125. Nye HJ, Herrington WG. Metformin: the safest hypoglycaemic agent in chronic kidney disease? Nephron Clin Pract. 2011;118:c380–3.
126. Hulisz DT, Bonfiglio MF, Murray RD. Metformin-associated lactic acidosis. J Am Board Fam Pract. 1998;11:233–6.
127. Duong JK, Roberts DM, Furlong TJ, Kumar SS, Greenfield JR, Kirkpatrick CM, et al. Metformin therapy in patients with chronic kidney disease. Diabetes Obes Metab. 2012;14:963–5.
128. Lalau JD, Race JM. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentrations. Drug Saf. 1999;20:377–84.
129. Frid A, Sterner GN, Löndahl M, Wiklander C, Cato A, Vinge E, et al. Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations. Diabetes Care. 2010;33:1291–3.
130. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care. 2011;34:1431–7.
131. Cignarelli A, Laviola L, Stefanelli G, Garruti G, Logoluso F, Morea N, et al. Metformin use in diabetics with reduced kidney function: prescription pattern in 4,414 subjects with type 2 diabetes and different eGFR levels. Diabetologia. 2013;56(Suppl 1):S387 (Abstract).
132. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S, et al. Reduction of Atherothrombosis for Continued Health (REACH) Registry Investigators. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892–9.
133. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;4:CD002967.
134. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA. 2014;312:2668–75.
135. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia. 1996;39:1617–24.
136. Jönsson A, Rydberg T, Sterner G, Melander A. Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol. 1998;53:429–35.
137. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol. 2001;57:147–52.
138. Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, et al. Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther. 2000;67:7–15.
139. Devineni D, Walter YH, Smith HT, Lee JS, Prasad P, McLeod JF. Pharmacokinetics of nateglinide in renally impaired diabetic patients. J Clin Pharmacol. 2003;43:163–70.
140. Hasslacher C. Multinational Repaglinide Renal Study Group. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care. 2003;26:886–91.
141. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompôr T, Eckland D. The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol. 2003;55:368–74.
142. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol. 2003;43:252–9.
143. Agrawal A, Sautter MC, Jones NP. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Clin Ther. 2003;25:2754–64.
144. Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30:1862–4.
145. Boulton DW, Li L, Frevert EU, Tang A, Castaneda L, Vachharajani NN, et al. Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clin Pharmacokinet. 2011;50:253–65.
146. He YL, Kulmatycki K, Zhang Y, Zhou W, Reynolds C, Ligueros-Saylan M, et al. Pharmacokinetics of vildagliptin in patients with varying degrees of renal impairment. Int J Clin Pharmacol Ther. 2013;51:693–703.
147. Karim A, Fleck P, Hetman L, Marbury T, Ravis W, Cannon C, et al. Single dose pharmacokinetics of dipeptidyl peptidase-4 inhibitor alogliptin in subjects with renal impairment [poster 538 P]. Diabetes. 2008;57(Suppl 1):A160 (Abstract).
148. Graefe-Mody U, Friedrich C, Port A, Ring A, Retlich S, Heise T, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab. 2011;13:939–46.
149. Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care. 2013;36:1067–73.
150. Chan JC, Scott R. Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab. 2008;10:545–55.
151. Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65:1230–9.
152. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well-tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13:523–32.
153. Lukashevich V, Schweizer A, Shao Q, Groop P-H, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab. 2011;13:947–54.
154. Kothny W, Shao Q, Groop P-H, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab. 2012;14:1032–9.
155. Schweizer A, Dejager S. Experience with vildagliptin in patients ≥ 75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther. 2013;4:257–67.
156. McGill JB, Sloan L, Newman J, Patel S, Sauce C, von Eynatten M, et al. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment. Diabetes Care. 2013;36:237–44.
157. Laakso M, Rosenstock J, Groop PH, Barnett AH, Gallwitz B, Hehnke U, et al. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015;38:e15–7.
158. De Nicola L, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis. 2014;64:16–24.
159. Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587–97.
160. Devineni D, Curtin CR, Marbury TC, Smith W, Vaccaro N, Wexler D, et al. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Ther. 2015;37:610–28.
161. Yale J-F, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463–73.
162. Yamout H, Perkovic V, Davies M, Woo V, de Zeeuw D, Mayer C, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40:64–74.
163. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85:962–71.
164. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, EMPA-REG RENAL Trial Investigators, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2:369–84.
165. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol. 2007;64:317–27.
166. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of GLP-1 analogue liraglutide. Br J Clin Pharmacol. 2009;68:898–905.
167. Aisenpreis U, Pfützner A, Giehl M, Keller F, Jehle PM. Pharmacokinetics and pharmacodynamics of insulin Lispro compared with regular insulin in haemodialysis patients with diabetes mellitus. Nephrol Dial Transplant. 1999;14(Suppl 4):5–6.
168. Johnson RD, Holcombe JH, Seger M, Cronin J. The disposition of insulin Lispro in patients with type 2 diabetes and impaired renal function. Diabetes. 1998;47(Suppl 1):A91 (Abstract).
169. Rave K, Heise T, Pfützner A, Heinemann L, Sawicki PT. Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care. 2001;24:886–90.
170. Ruggenenti P, Flores C, Aros C, Ene-Iordache B, Trevisan R, Ottomano C, et al. Renal and metabolic effects of insulin lispro in type 2 diabetic subjects with overt nephropathy. Diabetes Care. 2003;26:502–9.
171. Kiss I, Arold G, Roepstorff C, Bøttcher SG, Klim S, Haahr H. Insulin degludec: pharmacokinetics in patients with renal impairment. Clin Pharmacokinet. 2014;53:175–83.
172. Jacobsen LV, Popescu G, Plum A. Pharmacokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia. 2002;45(Suppl 1):A259 (Abstract).
173. Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013;4:113–21.
174. Baldwin D, Zander J, Munoz C, Raghu P, DeLange-Hudec S, Lee H, et al. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care. 2012;35:1970–4.
175. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G. Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med. 2003;20:642–5.
176. Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab. 2000;26(Suppl 4):73–85.
177. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM. Drug prescribing in renal failure. Dosing guidelines for adults. 4th ed. Philadelphia: American College of Physicians; 1999.
178. Meyers JL, Candrilli SD, Kovacs B. Type 2 diabetes mellitus and renal impairment in a large outpatient electronic medical records database: rates of diagnosis and antihyperglycemic medication dose adjustment. Postgrad Med. 2011;123:133–43.
179. Chen SY, Lee YC, Alas V, Greene M, Brixner D. Outcomes associated with nonconcordance to national kidney foundation guideline recommendations for oral antidiabetic drug treatments in patients with concomitant type 2 diabetes and chronic kidney disease. Endocr Pract. 2014;20:221–31.
180. Solini A, Penno G, Bonora E, Fondelli C, Orsi E, Trevisan R, Renal Insufficiency and Cardiovascular Events Study Group, et al. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. J Am Geriatr Soc. 2013;61:1253–61.